Scinopharm TaiwanTPE:1789 -2.68%76 Median PS Value is NT$27.06 as of Jun. 29, 2026, which is 100% below its 10-year median of 0.82. GuruFocus rates TPE:1789 with a GF Score™ of 76/100 and a GF Value™ of NT$27.02 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 544 Drug Manufacturers companies, Scinopharm Taiwan ranks better than 59.37% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Scinopharm Taiwan's Median PS Value or its related term are showing as below:
TPE:1789'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.62 Med: 0.82 Max: 0.94
Current: 0.74
During the past 13 years, the highest Price to Median PS Value of Scinopharm Taiwan was 0.94. The lowest was 0.62. And the median was 0.82.
TPE:1789's Price-to-Median-PS-Value is ranked better than 59.37% of 544
companies
in the Drug Manufacturers industry
Industry Median: 0.83
vs TPE:1789: 0.74
Scinopharm Taiwan (TPE:1789) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Scinopharm Taiwan's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
20.00
/
27.06
=
0.74
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinopharm Taiwan Median PS Value Related Terms
Scinopharm Taiwan Median PS Value Historical Data
* Premium members only.
The historical data trend for Scinopharm Taiwan's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinopharm Taiwan Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Scinopharm Taiwan's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 6.8075.
Scinopharm Taiwan's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$3.975.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinopharm Taiwan (TPE:1789) has a Median PS Value of NT$27.06 as of Jun. 29, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Scinopharm Taiwan and its competitors. This is 3200% above median its historical median of 0.82. Over the past decade, Scinopharm Taiwan's Median PS Value has ranged from 0.62 to 0.94. According to the industry distribution chart, Scinopharm Taiwan ranks #221 out of 544 companies in the Drug Manufacturers industry, placing it in the top 40.6%.
Is Scinopharm Taiwan's Median PS Value too high?
Scinopharm Taiwan's current Median PS Value of NT$27.06 is 3200% above median its 10-year median of 0.82. Over the past 10 years, this metric has ranged from a low of 0.62 to a high of 0.94. Based on the distribution chart, Scinopharm Taiwan ranks #221 out of 544 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Scinopharm Taiwan has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Median PS Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Scinopharm Taiwan ranks #221 out of 544 companies for Median PS Value. This puts Scinopharm Taiwan in the upper half of its industry. The industry median Median PS Value is 0.83. Historically, Scinopharm Taiwan's own Median PS Value has ranged from 0.62 to 0.94 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.83, based on 544 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Scinopharm Taiwan and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scinopharm Taiwan's current Median PS Value is NT$27.06, which is 3200% above median its own 10-year median of 0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.02, compared to a current price of NT$20.00 — trading 26% below its estimated fair value. The current Median PS Value is NT$27.06, which is 3200% above median its 10-year median of 0.82. Scinopharm Taiwan's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Median PS Value is NT$27.06 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?
Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued.
The current stock price of NT$20.00 is trading 26% below its estimated GF Value™ of NT$27.02.
GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.
Key valuation signals for TPE:1789:
Median PS Value: NT$27.06 (3200% above median its 10-year median of 0.82)
GF Value™: NT$27.02 vs. price of NT$20.00 (26% below fair value)
No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
76GF Score
Get the complete analysis for TPE:1789
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1789 has been successfully added to your 
